News

Caretaker Partners with Red One Medical to Expand Advanced Monitoring to More Veterans and Hospital Departments

Caretaker Medical and Red One Medical have partnered to enable safer healthcare for U.S. veterans at VA hospitals.

Caretaker’s VitalStream® will offer VA medical centers the ability to continuously and non-invasively monitor blood pressure, cardiac output, stroke volume, fluid responsiveness and other advanced hemodynamic parameters throughout all hospital departments. This level of monitoring has been previously unavailable outside of the operating room and intensive care unit, and is usually reserved for higher-risk patients and procedures since it involves invasive lines or uncomfortable and restrictive devices. VitalStream can expand advanced monitoring capabilities to more patients and can lead to earlier detection of clinical decompensation, promote root-cause identification and enable personalized treatment – all which can lead to better patient outcomes.

Low blood pressure (hypotension) in the perioperative period is common. Forty-four percent of noncardiac surgery patients experience intraoperative hypotension (IOH) with a mean arterial pressure (MAP) under 65 mmHg for over 10 minutes.1 And 48% of noncardiac surgery patients with IOH and 22% of patients without IOH experience postoperative hypotension of a MAP <65 mmHg within 48 hours of surgery.2 This increases the risk of perioperative morbidity and mortality including acute kidney injury (AKI) and myocardial injury.2,3 Many times, intraoperative BP is only checked every 2-5 minutes intraoperatively and every 15 minutes to 1 hour postoperatively using an oscillometric blood pressure cuff. This can result in undetected BP drops that increase the risk of poor outcomes for military veterans.

“We are excited to bring the VitalStream technology to VA hospitals and enable safer care for our nation’s veterans,” stated Johnny Mann, a military veteran and VP of Sales and Marketing at Caretaker Medical. “This innovative monitoring solution will empower VA clinicians to detect potential complications earlier, intervene more effectively, and ultimately improve patient outcomes for our heroes.”

VitalStream is the only wireless, wearable ICU-grade monitor to be clinically validated and FDA-cleared. It uses a low-pressure finger sensor and patented Pulse Decomposition Analysis (PDA™) to measure advanced hemodynamic parameters. Its compact size, portability and wireless design allows for continuity of monitoring throughout all phases of care.

“The use of VitalStream can benefit veterans in the emergency room, OR, catheterization lab, ICU and the floor by offering more comprehensive monitoring capabilities and a continuity of monitor, described Tim Fazekas, a Marine Corps veteran with extensive experience in field and hospital critical care, and clinical affairs specialist for Red One Medical. “It’s really the best non-invasive monitor available that a patient can wear.”

VitalStream is now available on the VA Federal Supply Schedule (VA FSS), a streamlined procurement method for the U.S Department of Veterans Affairs. The VA FSS provides VA hospitals with the ability to purchase the devices they need unincumbered.

VitalStream was previously added to ECAT, the procurement method for the Department of Defense (DOD), and is available to military units for use in the field.

“This expanded partnership shows our dedication to ensuring veterans have access to quality healthcare with best-in-class medical devices,” stated Red One Medical CEO, Charles Pollak. “VitalStream is an innovative patient monitor that can help improve care for all veterans and military members.”

Learn more here.

Recent News

10/11/2024

FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved ItovebiTM (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast

10/10/2024

RIVANNA initiates multi-site first-in-human study for Accuro XV musculoskeletal imaging system

RIVANNA®, developers of imaging-based medical solutions, has announced the launch of the first multi-site study employing the Accuro® XV musculoskeletal imaging system. This milestone follows a $30.5 million funding option executed in 2023 by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S.

10/09/2024

LifeNet Health’s Rapid Growth Continues with Acquisition of State-of-the-Art Virginia Beach Research Laboratory

A company that is a global leader in regenerative medicine has acquired a cutting-edge research laboratory in Virginia Beach. LifeNet Health will use the laboratory as a center of excellence for groundbreaking liver disease research and sports medicine applications. The dual function will provide better health solutions for a growing number of patients. Situated near